ConductScience.org, home

Paper4580472

Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones.

Thistle JL and 1 other. N Engl J Med, 1973. Cited by 328 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones. Papers, record 4580472. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4580472

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones.
PubMed
Journal
N Engl J Med
PubMed
Year
1973
PubMed
Publication types
Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article
PubMed
Citations, by iCite
328
iCite
Relative citation ratio, by iCite
12.6
iCite
Revised in PubMed
2016-11-23
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Thistle JLJ L
2Hofmann AFA F

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bile Acids and SaltsMajor topic
CholelithiasisMajor topic
Aspartate Aminotransferases
Chenodeoxycholic Acid
Cholecystography
Cholesterol
Cholic Acids
Clinical Trials as Topic
Digestive System
Female
Humans
Liver
Liver Function Tests
Male
Placebos
Solubility
Time Factors
Triglycerides

Source PubMed

Download CSV of topics

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 328 citations.

PMIDTitleJournalYearIn PapersSource
40545045The history and future of bile acid therapies.J Hepatol2025https://conductscience.org/library/papers/40545045PubMed
31988099Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/31988099PubMed
30936623Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model.J Clin Biochem Nutr2019https://conductscience.org/library/papers/30936623PubMed
29784843High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29784843PubMed
28729691Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose.Sci Rep2017https://conductscience.org/library/papers/28729691PubMed
25705637Recent advances in the development of farnesoid X receptor agonists.Ann Transl Med2015https://conductscience.org/library/papers/25705637PubMed
25646622Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).PLoS One2015https://conductscience.org/library/papers/25646622PubMed
25447797Impact of physiological levels of chenodeoxycholic acid supplementation on intestinal and hepatic bile acid and cholesterol metabolism in Cyp7a1-deficient mice.Steroids2015https://conductscience.org/library/papers/25447797PubMed
25214800Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease.Clin Exp Gastroenterol2014https://conductscience.org/library/papers/25214800PubMed
23447519Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.Eur J Endocrinol2013https://conductscience.org/library/papers/23447519PubMed
19429888Bile acids: developments new and very old.J Lipid Res2009https://conductscience.org/library/papers/19429888PubMed
18747563Medical treatment of cholelithiasis.West J Med1975https://conductscience.org/library/papers/18747563PubMed
17136860Isolation and determination of bile acids.Eur J Drug Metab Pharmacokinet2006https://conductscience.org/library/papers/17136860PubMed
7461466Chemical composition of gallstones resistant to dissolution therapy with chenodeoxycholic acid.Gut1980https://conductscience.org/library/papers/7461466PubMed
7374101Gallstone dissolution with chenodeoxycholic acid. A clinical study.Klin Wochenschr1980https://conductscience.org/library/papers/7374101PubMed
7076005Minimum effective dose of chenic acid for gallstone patients: reduction with bedtime administration and low cholesterol diet.Gut1982https://conductscience.org/library/papers/7076005PubMed
7075428Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey.Dig Dis Sci1982https://conductscience.org/library/papers/7075428PubMed
7009140Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.Drugs1981https://conductscience.org/library/papers/7009140PubMed
7000476Low-dose chenodeoxycholic acid for gallstone dissolution: a randomized trial in poor operative risk patients.Dig Dis Sci1980https://conductscience.org/library/papers/7000476PubMed
6986241Oral cholelitholysis--cheno versus urso: Japanese experience.Dig Dis Sci1980https://conductscience.org/library/papers/6986241PubMed

See all 54 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4580472

GET https://conductscience.org/api/papers/v1/4580472/cited_by?page=2